

Serial No. 09/500,135  
Docket No. GC527C1

**FAX COVER SHEET**

☐ Urgent  
☐ Confidential  
☐ Action Required  
☐ Reply Requested  
☐ For Your Info.

**TO:** Group Art Unit 1644

**OF:** USPTO

**Fax No.:** (703) 872-9306 (Before Final Facsimile No.)

**FROM:** Carol See for Kamrin MacKnight  
Patent Attorney

**LOCATION:** GENENCOR INTERNATIONAL, INC.  
Legal Department  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-7549  
Fax: 650-845-6504

**FAX RECEIVED**

MAR 19 2003

**GROUP 1600**

**DATE:** March 17, 2003

**NUMBER OF PAGES TO FOLLOW: 9**      **SENT BY: cas**

**RE:** Serial No. 09/500,135, Docket No. GC527C1

**Attachments:** Transmittal (1 page) in duplicate; Amendment and Response (7 pages).

The original of this facsimile will be sent to you via:

☐ Regular Mail    ☐ Overnight Mail    ☐ Hand Delivery    ☒ Will Not Be Sent

**NOTE:** The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone( 650/846-7517) and return the original transmission to us by mail.

GC527C1 FaxCover

Received from &lt;650 845 6504&gt; at 3/17/03 2:02:07 PM [Eastern Standard Time]

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Before Final Facsimile No. (703) 872-9306, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: March 17, 2003

By: 

Carol A. See

**PATENT**  
**Docket No. GC527C1**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Estell et al.	)	Group Art Unit: 1644
	)	
Serial No.: 09/500,135	)	Examiner: Saunders, D.
	)	
Filed: February 8, 2000	)	
	)	
For: Proteins Producing an Altered	)	
Immunogenic Response and Methods	)	
of Making and Using the Same	)	

**TRANSMITTAL LETTER**

Commissioner for Patents  
Washington, D.C. 20231


Sir:

In response to the Office Action dated January 7, 2003, enclosed please find the following document: Amendment and Response to Office Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527-C1). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: March 17, 2003

  
Kamrin T. MacKnight  
Registration No. 38,230

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-5838  
Fax: 650-845-6504

GC527-C1 T-OFFACT

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Before Final Facsimile No. (703) 872-9306, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: March 17, 2003

By: Carol A. See

Carol A. See

**PATENT**  
**Docket No. GC527C1**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Estell et al.

Serial No.: 09/500,135

Filed: February 8, 2000

For: Proteins Producing an Altered  
Immunogenic Response and Methods  
of Making and Using the Same

Group Art Unit: 1644

Examiner: Saunders, D.

**AMENDMENT AND RESPONSE TO OFFICE ACTION MAILED JANUARY 7, 2003**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

The present Amendment is filed in response to the Office Action mailed January 7, 2003. Instructions to amend the claims, with a clean version of the rewritten, added, and/or cancelled claims with instructions for entry pursuant to 37 C.F.R. §1.121 (c)(1)(i) are included beginning on page 2 of this communication. A marked-up version of the rewritten, added, and/or cancelled claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) is attached as Appendix I. A clean version of the entire set of pending claims pursuant to 37 C.F.R. §1.121 (c)(3) as they would appear following entry of this amendment is attached as Appendix II. None of the amendments to the Claims is intended to narrow the scope of any of the amended Claims within the meaning of *Festo*<sup>1</sup>.

<sup>1</sup> *Festo Corp. v. Shoketsu Kogyo Kabushiki Co.*, No. 95-1066, 2000 WL 1753646 (Fed. Cir. Nov. 29, 2000).

GC527C1 RESPAM